Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is set to participate in two fireside chats, enhancing its visibility in the oncology and healthcare sectors. The events are scheduled for:
- Stifel 2023 Targeted Oncology Days on April 26, 2023, at 12:30 p.m. ET
- BofA Securities 2023 Health Care Conference on May 9, 2023, at 10:00 a.m. PT
Both discussions will be webcast live, accessible on Relay Therapeutics’ website, with archived replays available for 30 days post-event. Relay Therapeutics is a clinical-stage precision medicine company dedicated to revolutionizing drug discovery through innovative computational and experimental technologies, focusing on small molecule therapeutic discovery in oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) announced promising initial clinical data for RLY-2608, an investigational allosteric PI3Kα inhibitor. The data demonstrated sustained target exposure of over 80% in mutant PI3Kα inhibition across various doses. Notably, no Grade 3 hyperglycemia, rash, or diarrhea, common treatment discontinuation events, were observed. A confirmed partial response was recorded in a breast cancer patient with extensive prior therapies. The ongoing ReDiscover trial, which began in December 2021, aims to evaluate this drug's safety and efficacy in patients with unresectable or metastatic solid tumors. Relay plans to initiate expansion cohorts in the second half of 2023. The results suggest RLY-2608 could transform treatment for patients with diverse PI3Kα mutations and improve the therapeutic index of PI3Kα inhibitors.